449 related articles for article (PubMed ID: 24485799)
1. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Karthik S; Sankar R; Varunkumar K; Ravikumar V
Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
[TBL] [Abstract][Full Text] [Related]
2. Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
Karthik S; Sankar R; Varunkumar K; Anusha C; Ravikumar V
Biomed Pharmacother; 2015 Feb; 69():337-44. PubMed ID: 25661379
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
Vinodhkumar R; Song YS; Devaki T
Biomed Pharmacother; 2008 Feb; 62(2):85-93. PubMed ID: 17644301
[TBL] [Abstract][Full Text] [Related]
4. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Denlinger CE; Rundall BK; Jones DR
J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602
[TBL] [Abstract][Full Text] [Related]
6. Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.
Kim B; Kim SH; Jeong SJ; Sohn EJ; Jung JH; Lee MH; Kim SH
J Agric Food Chem; 2012 Oct; 60(39):9882-9. PubMed ID: 22967175
[TBL] [Abstract][Full Text] [Related]
7. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
[TBL] [Abstract][Full Text] [Related]
9. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
Sato A; Asano T; Ito K; Asano T
Urology; 2012 Apr; 79(4):966.e13-21. PubMed ID: 22296623
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
Bao L; Diao H; Dong N; Su X; Wang B; Mo Q; Yu H; Wang X; Chen C
Cell Biol Toxicol; 2016 Dec; 32(6):469-482. PubMed ID: 27423454
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
12. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Denlinger CE; Keller MD; Mayo MW; Broad RM; Jones DR
J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1078-86. PubMed ID: 15052205
[TBL] [Abstract][Full Text] [Related]
13. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Sato A; Asano T; Ito K; Sumitomo M; Asano T
BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
[TBL] [Abstract][Full Text] [Related]
14. Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells.
Imesch P; Fink D; Fedier A
Fertil Steril; 2010 Dec; 94(7):2838-42. PubMed ID: 20605144
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
19. A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).
Harrison SJ; Bishton M; Bates SE; Grant S; Piekarz RL; Johnstone RW; Dai Y; Lee B; Araujo ME; Prince HM
Epigenomics; 2012 Oct; 4(5):571-89. PubMed ID: 23130838
[TBL] [Abstract][Full Text] [Related]
20. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
